Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

2.

Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.

Rodríguez-Barrios F, Pérez C, Lobatón E, Velázquez S, Chamorro C, San-Félix A, Pérez-Pérez MJ, Camarasa MJ, Pelemans H, Balzarini J, Gago F.

J Med Chem. 2001 Jun 7;44(12):1853-65.

PMID:
11384232
3.

Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.

Pelemans H, Aertsen A, Van Laethem K, Vandamme AM, De Clercq E, Pérez-Pérez MJ, San-Félix A, Velázquez S, Camarasa MJ, Balzarini J.

Virology. 2001 Feb 1;280(1):97-106.

4.

Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.

Van Laethem K, Schmit JC, Pelemans H, Balzarini J, Witvrouw M, Pérez-Pérez MJ, Camarasa MJ, Esnouf RM, Aquaro S, Cenci A, Perno CF, Hermans P, Sprecher S, Ruiz L, Clotet B, Van Wijngaerden E, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM.

AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):825-33.

PMID:
10875608
6.
7.

A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152.

Pelemans H, Esnouf RM, Parniak MA, Vandamme AM, De Clercq E, Balzarini J.

J Gen Virol. 1998 Jun;79 ( Pt 6):1347-52.

PMID:
9634074
10.
11.

Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

Pelemans H, Esnouf R, Dunkler A, Parniak MA, Vandamme AM, Karlsson A, De Clercq E, Kleim JP, Balzarini J.

J Virol. 1997 Nov;71(11):8195-203.

12.

Reverse transcriptase fidelity and HIV-1 variation.

Balzarini J, Pelemans H, De Clercq E, Karlsson A, Kleim JP.

Science. 1997 Jan 10;275(5297):229-30; author reply 230-1. No abstract available.

PMID:
8999551
13.

Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.

Balzarini J, Pelemans H, Karlsson A, De ClercQ E, Kleim JP.

Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13152-7.

14.

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

Balzarini J, Wedgwood O, Kruining J, Pelemans H, Heijtink R, De Clercq E, McGuigan C.

Biochem Biophys Res Commun. 1996 Aug 14;225(2):363-9.

PMID:
8753770
15.
16.

Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.

Balzarini J, Pelemans H, Pérez-Pérez MJ, San-Félix A, Camarasa MJ, De Clercq E, Karlsson A.

Mol Pharmacol. 1996 May;49(5):882-90.

PMID:
8622638
17.
18.

Characterization of the Rhizobium leguminosarum biovar phaseoli nifA gene, a positive regulator of nif gene expression.

Michiels J, D'hooghe I, Verreth C, Pelemans H, Vanderleyden J.

Arch Microbiol. 1994;161(5):404-8.

PMID:
8042903

Supplemental Content

Loading ...
Support Center